AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23510529
Drug: Fluoxetine (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (10-20 mg/day) plus placebo
Trial: 21608221
Drug: Weifuchun Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weifuchun Tablet (Control)
Trial: 16573982
Drug: No preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preparation (Cohort 1)
Trial: 15017515
Drug: 5-aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminosalicylic acid 1.0 g 3 times a day
Trial: 15017515
Drug: 5-aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminosalicylic acid 0.5 g 3 times a day
Trial: 15017515
Drug: 5-aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminosalicylic acid 1.5 g 3 times a day
Trial: 15017515
Drug: 5-aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminosalicylic acid (all doses)
Trial: 3554818
Drug: Methylphenidate (5
RxNorm normalized name: methylphenidate (50/50 release) 20 mg/24 hr oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (5 to 20 mg/d)
Trial: 30274655
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus healthy lifestyle instruction
Trial: 26108445
Drug: Topical combination
RxNorm normalized name: soap TOPICAL COMBINATION PACKAGE (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical combination therapy with maxacalcitol ointment and betamethasone butyrate propionate ointment (BBP)
Trial: 26108445
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid (BBP) alone
Trial: 25187436
Drug: Sodium- and
RxNorm normalized name: sodium benzoate and sodium phenylacetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium- and fluid-restricted diet (0.8 g/day sodium and 800 mL/day fluid)
Trial: 25187436
Drug: Unrestricted diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unrestricted diet (4 g/day sodium and unlimited fluid intake)
Trial: 24097171
Drug: Contrast water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast water therapy (CT)
Trial: 15827094
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate 25 mg
Trial: 15827094
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate 50 mg
Trial: 15827094
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate 125 mg
Trial: 15827094
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate 300 mg
Trial: 15827094
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate 600 mg
Trial: 18404076
Drug: Continuous beta-blocker
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous beta-blocker (BB)
Trial: 15217715
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (in a double-blind, placebo-controlled, randomized clinical trial)
Trial: 7810251
Drug: Dexamethasone (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (500 mg intravenous infusion within 3 h after trauma, followed by 200 mg after 3 h, then 8 times 200 mg at 6 hourly intervals, total dose 2.3 g in 51 hours)
Trial: 26285766
Drug: Iniparib with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iniparib with monthly temozolomide (mTMZ) dosing (150‐200 mg/m(2) days 1‐5/28 days)
Trial: 26285766
Drug: Iniparib with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iniparib with continuous temozolomide (cTMZ) dosing (75 mg/m(2)/days × 6 weeks)
Trial: 26285766
Drug: Recommended phase
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended phase 2 dosing of iniparib
Trial: 18707846
Drug: Infliximab (3mg/kg)
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab (3mg/kg) administered at baseline
Trial: 16939405
Drug: Low-level whole
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level whole body vibration (30 Hz, 0.3g) for 10 minutes daily for 12 months
Trial: 16939405
Drug: Low-level whole
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level whole body vibration (30 Hz, 0.3g) for 10 minutes daily for 12 months (per protocol analysis)
Trial: 14510790
Drug: Mild laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild laser treatment using an argon green laser
Trial: 9108387
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human IL-10 (rhIL-10; 25 microg/kg) pre-treatment
Trial: 9108387
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human IL-10 (rhIL-10; 25 microg/kg) post-treatment
Trial: 9108387
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human IL-10 (rhIL-10; 25 microg/kg) pre-treatment and post-treatment
Trial: 29459150
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 1 cartridge of 4% prilocaine plain plus 1 cartridge of 2% lidocaine with 1:100,000 epinephrine
Trial: 29459150
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 2 cartridges of 2% lidocaine with 1:100,000 epinephrine
Trial: 29459150
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 4% prilocaine plain plus 2% lidocaine with 1:100,000 epinephrine
Trial: 23131288
Drug: Ulinastatin (UTI)
RxNorm normalized name: phenazopyridine hydrochloride Oral Tablet [UTI Relief]
DrugBank: Ulinastatin (DB12038)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulinastatin (UTI) treatment, 200 kU every 8 hours
Trial: 20367218
Drug: 40 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g/day palatinose-blended sugar (PS group)
Trial: 20367218
Drug: 40 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g/day sucrose (S group)
Trial: 15983450
Drug: 30% inspired
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% inspired oxygen in air plus intravenous administration of saline
Trial: 15983450
Drug: 80% inspired
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80% inspired oxygen in air plus intravenous administration of saline
Trial: 10372238
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg fenfluramine three times a day and 37.5 mg phentermine daily (n = 23)
Trial: 9092419
Drug: Aspirin (100-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100-300 mg/day)
Trial: 9092419
Drug: Aspirin (for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (for primary prevention)
Trial: 1931470
Drug: Magnesium hydroxide
RxNorm normalized name: Magnesium Hydroxide
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium hydroxide (850 mg) with non-micronised glibenclamide (2.5 mg)
Trial: 1931470
Drug: Magnesium hydroxide
RxNorm normalized name: Magnesium Hydroxide
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium hydroxide (850 mg) with micronised glibenclamide (1.75 mg)
Trial: 1931470
Drug: Water only
RxNorm normalized name: Water only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water only (150 ml) with micronised glibenclamide (1.75 mg)
Trial: 1931470
Drug: Water only
RxNorm normalized name: Water only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water only (150 ml) with non-micronised glibenclamide (2.5 mg)
Trial: 6799077
Drug: Propranolol 40
RxNorm normalized name: propranolol 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 40 mg four times a day
Trial: 3610515
Drug: Topical benzydamine
RxNorm normalized name: benzydamine Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzydamine
Trial: 1774006
Drug: Oral diclofenac
RxNorm normalized name: diclofenac Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diclofenac
Trial: 25128052
Drug: Hospital treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital treatment as usual (7 days)
Trial: 25128052
Drug: Early assisted
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early assisted discharge (3 days in hospital followed by treatment at home)
Trial: 22054782
Drug: Losartan/HCTZ combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan/HCTZ combination therapy
Trial: 22054782
Drug: High-dose amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose amlodipine monotherapy
Trial: 18949456
Drug: Conventional regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional regimens (n = 109) of propofol, midazolam or lorazepam combined with fentanyl or morphine.
Trial: 17125957
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (n = 21)
Trial: 16372801
Drug: Hydrocortisone (cream)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone (cream)
Trial: 16372801
Drug: Hydrocortisone (ointment)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone (ointment)
Trial: 16372801
Drug: Hydrocortisone butyrate
RxNorm normalized name: Hydrocortisone Butyrate
DrugBank: Hydrocortisone butyrate (DB14540)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocortisone butyrate (cream)
Trial: 16372801
Drug: Hydrocortisone butyrate
RxNorm normalized name: Hydrocortisone Butyrate
DrugBank: Hydrocortisone butyrate (DB14540)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocortisone butyrate (ointment)
Trial: 16372801
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (cream)
Trial: 16372801
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (ointment)
Trial: 10868615
Drug: Single-dose miconazole
RxNorm normalized name: Miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single-dose miconazole nitrate (1200 mg) vaginal ovule
Trial: 10868615
Drug: Monistat 7
RxNorm normalized name: Monistat 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monistat 7 (miconazole nitrate 2%) Vaginal Cream
Trial: 1425900
Drug: Piroxicam suppository
RxNorm normalized name: piroxicam Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam suppository (20 mg)
Trial: 30986738
Drug: Brief cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief cognitive behavioral therapy (n = 76)
Trial: 30071980
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (n = 76)
Trial: 30348185
Drug: GMCT (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMCT (800 mg daily)
Trial: 22840413
Drug: Transversus abdominis
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transversus abdominis plane (TAP) block with 20 mL of 0.5% ropivacaine with epinephrine 1:200,000
Trial: 18230831
Drug: Methylprednisolone (MP)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (MP) 500 mg administered intravenously over three consecutive days, in four cycles at 4 weekly intervals (total 6 g of MP).
Trial: 18230831
Drug: Placebo (PL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL) administered intravenously over three consecutive days, in four cycles at 4 weekly intervals.
Trial: 15851425
Drug: Gaviscon Infant
RxNorm normalized name: Gaviscon
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gaviscon Infant (625 mg in 225 ml milk)
Trial: 15851425
Drug: Placebo (mannitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (mannitol and Solvito N, 625 mg in 225 ml milk)
Trial: 15320475
Drug: Endothelin receptor
RxNorm normalized name: Endothelin receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endothelin receptor antagonists (selective ET-A and non-selective ET-A/B receptor antagonists)
Trial: 15320475
Drug: Investigational drugs
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR DEMENTIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drugs targeting endothelin system
Trial: 10400482
Drug: 64 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 64 mg/day beta-carotene for 1 week
Trial: 1810525
Drug: Meclofenamate sodium
RxNorm normalized name: Meclofenamate Sodium
DrugBank: Meclofenamic acid (DB00939)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meclofenamate sodium (100 mg)
Trial: 1806546
Drug: Piroxicam-beta-cyclodextrin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam-beta-cyclodextrin (20 mg)
Trial: 22709952
Drug: Seasonal inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seasonal inactivated trivalent influenza vaccine (TIV)
Trial: 15089813
Drug: Quinidine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine (600 mg)
Trial: 1951002
Drug: Mexiletine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine (400 mg)
Trial: 7096998
Drug: Human diploid
RxNorm normalized name: rabies vaccine, human diploid cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human diploid cell rabies vaccine, administered in 0.1 ml volumes intradermally (i.d.) or as 1.0 ml intramuscularly (i.m.)
Trial: 7096998
Drug: Three injections
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three injections of human diploid cell rabies vaccine
Trial: 7096998
Drug: Booster doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster doses administered by the subcutaneous (s.c.) or i.d. route
Trial: 7096998
Drug: Intradermal (i.d.)
RxNorm normalized name: IOBENGUANE I 123
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (i.d.) immunization
Trial: 27787269
Drug: ATX-101 2
RxNorm normalized name: ATX-101
DrugBank: ATX-101 (DB05780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATX-101 2 mg/cm
Trial: 27787269
Drug: Topical and
RxNorm normalized name: norgestimate and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical and injectable lidocaine
Trial: 27787269
Drug: Ibuprofen and
RxNorm normalized name: Ibuprofen and Famotidine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen and loratadine
Trial: 27787269
Drug: ATX-101 treatment
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ATX-101 treatment
Trial: 22003214
Drug: Ropivacaine 0.75%
RxNorm normalized name: ROPivacaine 0.75% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.75% (25 mL) injected cephalad to the peroneal-tibial division (Group A)
Trial: 22003214
Drug: Ropivacaine 0.75%
RxNorm normalized name: ROPivacaine 0.75% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.75% (25 mL) injected caudad to the peroneal-tibial division (Group B)
Trial: 10941879
Drug: CLA supplementation
RxNorm normalized name: CLA
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CLA supplementation (3 g/d)
Trial: 1464274
Drug: Slow discontinuation
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow discontinuation of antiepileptic drugs (AEDs)
Trial: 1464274
Drug: Routine maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine maintenance of antiepileptic drugs (AEDs)
Trial: 28641407
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg/day and atorvastatin 20 mg/day
Trial: 25621239
Drug: Intranasal splints
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal splints after PIT (Group A)
Trial: 25621239
Drug: No intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intranasal splints after PIT (Group B)
Trial: 21674711
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of symptom assessment plus endoscopic evidence of recurrence
Trial: 19506137
Drug: Placebo (isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (isotonic sodium chloride solution infusion)
Trial: 16469978
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids (3.6 g n‐3 fatty acids/d)
Trial: 11685167
Drug: Amiodarone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (1 g/d intravenously for 48 hours, then 400 mg/d orally until discharge)
Trial: 11685167
Drug: Propranolol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (1 mg intravenously every 6 hours for 48 hours, then 20 mg orally four times a day until discharge)
Trial: 9799348
Drug: Pethidine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine (100 mg by intramuscular injection)
Trial: 9799348
Drug: Diclofenac (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (75 mg by intramuscular injection)
Trial: 3180632
Drug: Bumetanide (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide (3 mg oral and intravenous doses)
Trial: 30742566
Drug: Duvelisib 25
RxNorm normalized name: duvelisib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duvelisib 25 mg orally twice daily
Trial: 3598997
Drug: Nifedipine, 20
RxNorm normalized name: Nifedipine, 20 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine, 20 mg twice daily for 4 weeks
Trial: 3891346
Drug: Nifedipine treatment
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine treatment
Trial: 3598997
Drug: Longterm treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longterm treatment (16-20 weeks) with Nifedipine
Trial: 8402326
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 3 months
Trial: 29690916
Drug: Combined protocol
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined protocol for the treatment of SAM and MAM
Trial: 29690916
Drug: Standard protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard protocol (national treatment protocol)
Trial: 24213958
Drug: Active tDCS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active tDCS (anodal stimulation of the motor cortex, 10 days, 20 minutes, 2 mA, twice a day)
Trial: 19174493
Drug: Capromorelin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capromorelin (10 mg three times/week, 3 mg twice a day, 10 mg each night, and 10 mg twice a day)
Trial: 19174493
Drug: Capromorelin (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capromorelin (various doses)
Trial: 16300168
Drug: Aliskiren 150
RxNorm normalized name: aliskiren 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 150 mg with Lovastatin 40 mg
Trial: 16300168
Drug: Aliskiren 150
RxNorm normalized name: aliskiren 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 150 mg with Atenolol 100 mg
Trial: 16300168
Drug: Aliskiren 150
RxNorm normalized name: aliskiren 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 150 mg with Celecoxib 200 mg
Trial: 16300168
Drug: Aliskiren 150
RxNorm normalized name: aliskiren 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 150 mg with Cimetidine 800 mg
Trial: 7714229
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of oral SDZ ENS-163 with intravenous saline
Trial: 7714229
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with intravenous scopolamine